Menlo Park, Calif. and DALLAS – January 11, 2020 – ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that David Lockhart, CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:30 p.m. ET on Wednesday, January 13, 2021.
An archived replay of the presentation will be available on the Company’s website, www.recodetx.com, for 30 days.
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Company’s diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively. The Company is leveraging its lipid nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. For more information, visit www.recodetx.com
Steve E. Kunszabo